Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou's Alphamab Oncology Approved to IPO on Hong Kong Exchange

publication date: Jul 16, 2019

Alphamab Oncology, which was spun out of Suzhou Alphamab last year, was approved to IPO in Hong Kong under the Exchange's pre-revenue rules. The bi-specifics company has eight oncology molecules in development, four of them in clinical trials, and will use the IPO proceeds to support clinical development of its portfolio. Alphamab expects KNO46, potentially a first-in-class bispecific antibody against CTLA-4 and PD-1, to be fast-tracked towards China approval for nasopharyngeal carcinoma in 2022. It is currently in a Phase Ib/II trial. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital